Effect of Covid-19 on chronic kidney disease progression
Covid-19 对慢性肾脏病进展的影响
基本信息
- 批准号:10194834
- 负责人:
- 金额:$ 12.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-04 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAcuteAcute Kidney Tubular NecrosisAcute Renal Failure with Renal Papillary NecrosisAdultAdverse effectsAffectAgeAngiopoietin-2Automobile DrivingAutopsyBiological MarkersBiopsyBlood VesselsBlood coagulationBlood specimenBostonCOVID-19COVID-19 diagnosisCOVID-19 pandemicCOVID-19 patientCOVID-19 severityCase-Control StudiesCell Adhesion MoleculesChronic Kidney FailureCollaborationsComplicationCoronavirusCreatinineDataDiseaseDisease OutcomeDisease ProgressionEnd stage renal failureEndotheliumEnrollmentEthnic OriginFibrin fragment DFunctional disorderFutureGenderGlomerular Filtration RateGoalsHealthHealthcare SystemsHospitalsHumanICAM1 geneImmunophenotypingInfectionInjuryInjury to KidneyInstitutesInterventionKidneyKidney DiseasesLeadLettersLiteratureLong-Term EffectsManuscriptsMassachusettsMeasuresMentored Patient-Oriented Research Career Development AwardModelingMorbidity - disease rateNephrologyOrganOutcomePathogenesisPathway interactionsPatientsPeripheral Blood Mononuclear CellPlasmaPopulationPredictive ValuePreparationProteinuriaProteomicsQuality of lifeRaceRenal Replacement TherapyRenal functionResearchRetrospective cohort studyRiskRisk FactorsRoleSARS-CoV-2 infectionSamplingScientistSeverity of illnessSiteSurvival AnalysisSurvivorsTestingTimeTubular formationUrineVascular Endothelial Growth FactorsVascular EndotheliumViralVirusVirus DiseasesWorkbiobankcareerclinical careclinical predictorsclinically significantcohortcomorbidityethnic minority populationexperienceflexibilityhazardhigh riskimprovedkidney biopsykidney dysfunctionmortalitypandemic diseasepathogenpatient populationpredictive modelingprogramsracial minorityrate of changerepositoryrespiratorysevere COVID-19skillstranslational scientistvon Willebrand Factor
项目摘要
Project Summary
Coronavirus disease 2019 (COVID-19) is a respiratory illness that has sickened over 7 million people
worldwide and continues to rapidly spread. The causal virus, severe acute respiratory coronavirus 2 (SARS-
CoV-2), targets the kidney, and acute kidney injury is a common complication, affecting 20-40% of hospitalized
patients. Kidney biopsies and autopsies show a unique pathogenesis including acute tubular injury with
significant numbers demonstrating prominent vascular endothelial injury and microthrombi. Although high rates
of acute kidney injury have been described, we currently have no data on the medium to long-term effects of
COVID-19 on kidney function. Patients with underlying chronic kidney disease (CKD) are most vulnerable to
kidney injury, and a subset may experience rapid CKD progression after COVID-19. Endothelial injury, which is
a key feature of severe COVID-19 found on biopsies and autopsies of multiple affected organs, may be more
severe and irreversible in patients who already have kidney diseases that affect the microvasculature. CKD is
one of the most common comorbidities among patients with COVID-19, which has currently affected
approximately 5% of the US population. Accelerated CKD progression in a large number of patients with
preexisting illness who survive COVID-19 will have a substantial adverse effect on patients’ quality of life,
increase morbidity and mortality, and will be a large burden to the US healthcare system. Therefore, there is a
pressing need to understand how COVID-19 affects eGFR decline, predictors of CKD progression, and
underlying mechanisms driving CKD progression after COVID-19. In Aim 1, we will evaluate the association of
COVID-19 with changes in estimated glomerular filtration rate (eGFR) and determine clinical predictors that are
associated with rapid eGFR decline (defined by > 25% loss of eGFR or need for renal replacement therapy
lasting more than 90 days) occurring within 1 year after diagnosis of COVID-19. Elucidation of these risk
factors will allow us to identify patients who are at high risk of progressive CKD after COVID-19. This proposal
benefits from collaboration with the Massachusetts Center for Pathogen Research, allowing us access to
human blood samples from an ongoing biobank of patients with COVID-19 that is enrolling across multiple
sites in Massachusetts. In Aim 2, we will determine 1-year kidney function outcomes in the patients enrolled in
this biobank and perform a case-control study to determine if patients who experience rapid eGFR decline
within 1 year after infection have increased markers of endothelial activation and blood coagulation at the time
of COVID-19 compared to those with stable kidney function. The larger goal of this proposal is to build
preliminary data in preparation for an R01 application over the next 12-24 months to study mechanisms of
CKD progression in patients with COVID-19. Ultimately, we hope to improve our understanding of COVID-19’s
effect on kidney function and identify interventions to decrease new-onset CKD and progression to end-stage
renal disease in survivors.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Meghan E. Sise其他文献
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
钠-葡萄糖协同转运蛋白 2 抑制剂在痛风患者中的临床益处
- DOI:
10.1038/s41584-024-01092-x - 发表时间:
2024-03-12 - 期刊:
- 影响因子:32.700
- 作者:
Chio Yokose;Natalie McCormick;Abhishek Abhishek;Nicola Dalbeth;Tristan Pascart;Frédéric Lioté;Angelo Gaffo;John FitzGerald;Robert Terkeltaub;Meghan E. Sise;James L. Januzzi;Deborah J. Wexler;Hyon K. Choi - 通讯作者:
Hyon K. Choi
Meghan E. Sise的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Meghan E. Sise', 18)}}的其他基金
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
免疫检查点抑制剂治疗癌症后导致急性和慢性肾功能下降的机制
- 批准号:
10837486 - 财政年份:2023
- 资助金额:
$ 12.6万 - 项目类别:
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
免疫检查点抑制剂治疗癌症后导致急性和慢性肾功能下降的机制
- 批准号:
10334688 - 财政年份:2022
- 资助金额:
$ 12.6万 - 项目类别:
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
免疫检查点抑制剂治疗癌症后导致急性和慢性肾功能下降的机制
- 批准号:
10576290 - 财政年份:2022
- 资助金额:
$ 12.6万 - 项目类别:
Effect of Covid-19 on chronic kidney disease progression
Covid-19 对慢性肾脏病进展的影响
- 批准号:
10341216 - 财政年份:2021
- 资助金额:
$ 12.6万 - 项目类别:
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression
根除丙型肝炎病毒对慢性肾脏病进展的影响
- 批准号:
9923651 - 财政年份:2018
- 资助金额:
$ 12.6万 - 项目类别:
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression
根除丙型肝炎病毒对慢性肾脏病进展的影响
- 批准号:
10398139 - 财政年份:2018
- 资助金额:
$ 12.6万 - 项目类别:
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression
根除丙型肝炎病毒对慢性肾脏病进展的影响
- 批准号:
10159102 - 财政年份:2018
- 资助金额:
$ 12.6万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 12.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 12.6万 - 项目类别:
Standard Grant